- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Docecad® | docetaxel anhydrous | EmDOC | Taxotere®
docetaxel is an approved drug (FDA (1996), EMA (1995))
Compound class: Synthetic organic
Comment: Docetaxel is a pan tubulin inhibitor which is a semi-synthetic analogue of paclitaxel (taxol), an extract from the bark of the rare Pacific yew tree Taxus brevifolia.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: docetaxel
|No information available.|
|Summary of Clinical Use|
|Docetaxel is an anti-mitotic compound used mainly for the treatment of breast, ovarian, prostate, and non-small cell lung cancers.
Preliminary results from a recent clinical trial (June 2014) which compared hormone-depleting therapy alone with hormone-depleting therapy plus docetaxel in newly diagnosed metastatic prostate cancer patients, indicates that the combination treatment increases median survival after more than two years and delays cancer progression by around one year (unpublished results).
|Mechanism Of Action and Pharmacodynamic Effects|
|Docetaxel reversibly binds to microtubules with high affinity, hyper-stabilising their structure and limiting the flexibility of the cell's cytoskeleton, thus compromising cell growth, division and ultimately viability.|